The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Research Report 2025

Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1899394

No of Pages : 82

Synopsis
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that reduce pain, decrease fever, prevent blood clots and, in higher doses, decrease inflammation. Side effects depend on the specific drug, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack and kidney disease.
The global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Report Scope
The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche (Genentech)
Amgen
B-MS
Merck
Pfizer
Novartis
Eli Lilly and Company
Johnson & Johnson
GSK
Sanofi
Boehringer Ingelheim
Zhejiang Jiuzhou Pharmaceutical
Segment by Type
Aspirin
Ibuprofen
Naproxen
Celecoxib
Others
Segment by Application
Drug Store
Hospital Pharmacies
Online
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Aspirin
1.2.3 Ibuprofen
1.2.4 Naproxen
1.2.5 Celecoxib
1.2.6 Others
1.3 Market by Application
1.3.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Drug Store
1.3.3 Hospital Pharmacies
1.3.4 Online
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Perspective (2019-2030)
2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Growth Trends by Region
2.2.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Historic Market Size by Region (2019-2024)
2.2.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Forecasted Market Size by Region (2025-2030)
2.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Dynamics
2.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Industry Trends
2.3.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Drivers
2.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Challenges
2.3.4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Players by Revenue
3.1.1 Global Top Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Players by Revenue (2019-2024)
3.1.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Revenue Market Share by Players (2019-2024)
3.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Revenue
3.4 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Concentration Ratio
3.4.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Revenue in 2023
3.5 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Key Players Head office and Area Served
3.6 Key Players Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Product Solution and Service
3.7 Date of Enter into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Breakdown Data by Type
4.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Historic Market Size by Type (2019-2024)
4.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Forecasted Market Size by Type (2025-2030)
5 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Breakdown Data by Application
5.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Historic Market Size by Application (2019-2024)
5.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size (2019-2030)
6.2 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2019-2024)
6.4 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size (2019-2030)
7.2 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2019-2024)
7.4 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size (2019-2030)
8.2 Asia-Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size (2019-2030)
9.2 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2019-2024)
9.4 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size (2019-2030)
10.2 Middle East & Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche (Genentech)
11.1.1 Roche (Genentech) Company Detail
11.1.2 Roche (Genentech) Business Overview
11.1.3 Roche (Genentech) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.1.4 Roche (Genentech) Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.1.5 Roche (Genentech) Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.2.4 Amgen Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 B-MS
11.3.1 B-MS Company Detail
11.3.2 B-MS Business Overview
11.3.3 B-MS Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.3.4 B-MS Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.3.5 B-MS Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.4.4 Merck Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.5.4 Pfizer Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.6.4 Novartis Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.7.4 Eli Lilly and Company Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.7.5 Eli Lilly and Company Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.8.4 Johnson & Johnson Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.8.5 Johnson & Johnson Recent Development
11.9 GSK
11.9.1 GSK Company Detail
11.9.2 GSK Business Overview
11.9.3 GSK Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.9.4 GSK Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.9.5 GSK Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.10.4 Sanofi Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.10.5 Sanofi Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Detail
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.11.4 Boehringer Ingelheim Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Business (2019-2024)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’